Lyell Immunopharma (NASDAQ:LYEL) Trading Up 5.9%

Shares of Lyell Immunopharma, Inc. (NASDAQ:LYEL) were up 5.9% during mid-day trading on Thursday . The stock traded as high as $2.17 and last traded at $2.16. Approximately 158,847 shares traded hands during trading, a decline of 84% from the average daily volume of 985,758 shares. The stock had previously closed at $2.04.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reduced their price target on shares of Lyell Immunopharma from $8.00 to $6.00 and set a “buy” rating for the company in a research report on Thursday, February 29th.

Lyell Immunopharma Stock Up 9.3 %

The stock’s fifty day simple moving average is $2.15 and its 200 day simple moving average is $1.93.

Lyell Immunopharma (NASDAQ:LYEL) last announced its quarterly earnings results on Wednesday, February 28th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.01. The business had revenue of $0.01 million during the quarter, compared to the consensus estimate of $4.96 million. Lyell Immunopharma had a negative net margin of 180,486.14% and a negative return on equity of 32.67%. Equities research analysts expect that Lyell Immunopharma, Inc. will post -0.91 earnings per share for the current year.

Hedge Funds Weigh In On Lyell Immunopharma

Several hedge funds and other institutional investors have recently added to or reduced their stakes in LYEL. ProShare Advisors LLC boosted its position in Lyell Immunopharma by 35.2% in the 1st quarter. ProShare Advisors LLC now owns 52,739 shares of the company’s stock valued at $267,000 after buying an additional 13,726 shares during the period. JPMorgan Chase & Co. lifted its position in shares of Lyell Immunopharma by 11.6% during the 1st quarter. JPMorgan Chase & Co. now owns 518,404 shares of the company’s stock worth $2,618,000 after purchasing an additional 54,053 shares during the last quarter. Bank of New York Mellon Corp lifted its position in shares of Lyell Immunopharma by 447.4% during the 1st quarter. Bank of New York Mellon Corp now owns 390,166 shares of the company’s stock worth $1,970,000 after purchasing an additional 318,890 shares during the last quarter. MetLife Investment Management LLC purchased a new stake in shares of Lyell Immunopharma during the 1st quarter worth $427,000. Finally, Metropolitan Life Insurance Co NY purchased a new stake in shares of Lyell Immunopharma during the 1st quarter worth $50,000. Hedge funds and other institutional investors own 66.05% of the company’s stock.

About Lyell Immunopharma

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.